Market Place
Sourcing Support
Samsung Epis Holdings Unveils Q1 2026 Financial Performance
23 Apr 2026 //
PHARMIWEB
Samsung Bioepis Reveals Preclinical Data For ADC SBE303 At AACR
21 Apr 2026 //
INDPHARMAPOST
Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303
14 Apr 2026 //
BUSINESSWIRE
Sandoz Expands Biosimilar Collaboration With Samsung Bioepis
18 Mar 2026 //
FIERCE PHARMA
Samsung Bioepis Unveils Q1 2026 US Biosimilar Market Report
23 Jan 2026 //
BUSINESSWIRE
Samsung Epis Holdings Presents Updates At J.P. Morgan Health Conf
14 Jan 2026 //
BUSINESSWIRE
Samsung Bioepis Launches Byooviz, Biosimilar for Lucentis in EU
02 Jan 2026 //
BUSINESSWIRE
Samsung Bioepis` BYOOVIZ, Pre-Filled Syringe Approved In Europe
02 Dec 2025 //
BUSINESSWIRE
Samsung Bioepis Launches Denosumab Biosimilars, Obodence & Xbryk
01 Dec 2025 //
BUSINESSWIRE
Samsung Bioepis Settles Pyzchiva (Ustekinumab) in Europe
06 Nov 2025 //
BUSINESS WIRE
Samsung Bio Spins Off To Enhance Focus As CDMO
03 Nov 2025 //
PR NEWSWIRE
Samsung Bioepis to Launch Byooviz in Europe in January 2026
29 Oct 2025 //
BUSINESSWIRE
Samsung Bioepis Publishes Q4 2025 US Biosimilar Market Report
23 Oct 2025 //
BUSINESSWIRE
Samsung Bioepis Releases Q3 2025 U.S. Biosimilar Report
21 Jul 2025 //
BUSINESSWIRE
Harrow, Samsung Bioepis Ink US Ophthalmology Deal
18 Jul 2025 //
BUSINESSWIRE
Samsung Bioepis` Whitepaper Proposes Solutions for Policy Gaps
14 Jul 2025 //
BUSINESSWIRE
Samsung Bioepis Presents EPYSQLI™ Safety Data at EHA Congress
12 Jun 2025 //
BUSINESSWIRE
Samsung Bioepis Enters into a Strategic Partnership with Nipro
09 Jun 2025 //
BUSINESSWIRE
FDA Grants interchangeability to Samsung & Organon Hadlima Inj
27 May 2025 //
BUSINESSWIRE
Samsung Bioepis` Q2 2025 Report Highlights US Debut of Ustekinuma
24 Apr 2025 //
BUSINESSWIRE
Teva and Samsung Bioepis Launch EPYSQLI in the U.S.
07 Apr 2025 //
PRESS RELEASE
J&J sues Samsung Bioepis over contract breach for Stelara
27 Feb 2025 //
REUTERS
Samsung Bioepis Launches PYZCHIVA, Stelara Biosimilar In U.S.
24 Feb 2025 //
BUSINESSWIRE
Samsung Bioepis Gains EC Approval for Denosumab Biosimilar
18 Feb 2025 //
BUSINESSWIRE
FDA Approves Samsung Bioepis’ Ospomyv, Xbryk
15 Feb 2025 //
BUSINESSWIRE
Samsung Bioepis Releases Q1 2025 US Biosimilar Market Report
16 Jan 2025 //
GLOBENEWSWIRE
Samsung Bioepis, Teva Partner For Epysqli In US
10 Jan 2025 //
GLOBENEWSWIRE
Samsung Invests in Biomedicines for AI-Driven Protein Discovery
18 Dec 2024 //
PR NEWSWIRE
Samsung Gets Positive CHMP Opinion for Denosumab Biosimilars
15 Nov 2024 //
GLOBENEWSWIRE
Samsung Bioepis Q4 2024 US Biosimilar Market Report Released
10 Oct 2024 //
GLOBENEWSWIRE
Samsung Bioepis Presents Data On EPYSQLI At European Society
23 Sep 2024 //
GLOBENEWSWIRE
Samsung Bioepis and Biogen Receive Positive CHMP
20 Sep 2024 //
GLOBENEWSWIRE
Samsung Biologics Reports Record Quarter Due To Biosimilar Sales
24 Jul 2024 //
FIERCE PHARMA
FDA Approves Samsung Bioepis` EPYSQLI As Biosimilar To Soliris
22 Jul 2024 //
GLOBENEWSWIRE
AbbVie`s Humira loses some ground in high-stakes battle against biosimilars
12 Jul 2024 //
FIERCE PHARMA
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar
01 Jul 2024 //
GLOBENEWSWIRE
Italy starts probe into Lucentis biosimilar delay allegation
08 Jun 2024 //
PHARMAPHORUM
Samsung Bioepis Eculizumab Biosimilar EPYSQLI Post-Hoc Analysis At EHA
30 May 2024 //
GLOBENEWSWIRE
Samsung Biosimilar Sb16 Prolia: Switching Period Results At Ects 2024
27 May 2024 //
GLOBENEWSWIRE
Samsung Bioepis Releases Second Quarter 2024 US Biosimilar Market Report
08 Apr 2024 //
GLOBENEWSWIRE
Samsung Bioepis Initiates Ph 3 Trial for SB27, Proposed Biosimilar to Keytruda
05 Apr 2024 //
GLOBENEWSWIRE
Samsung Bioepis Releases First Quarter 2024 US Biosimilar Market Report
17 Jan 2024 //
GLOBENEWSWIRE
J&J, Samsung Bioepis ink Stelara biosimilar settlement
30 Nov 2023 //
FIERCE PHARMA
Samsung Bioepis & Organon Announce Acceptance of sBLA for Interchangeability Designation for HADLIMA
07 Nov 2023 //
GLOBENEWSWIRE
Samsung Bioepis Presents Phase 1 and 3 Clinical Results for SB16
15 Oct 2023 //
GLOBENEWSWIRE
Samsung Bioepis Presents Two Abstracts at EADV 2023 Congress
11 Oct 2023 //
GLOBENEWSWIRE
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Clinical Trial for SB15
07 Oct 2023 //
GLOBENEWSWIRE
Samsung Bioepis looks to acquire Biogen`s biosim unit: reports
03 Aug 2023 //
FIERCE PHARMA
Samsung Bioepis & Organon Announce Results from Study of SB5 Humira Biosimilar
01 Aug 2023 //
GLOBENEWSWIRE
Samsung Bioepis Releases its Second US Biosimilar Market Report
11 Jul 2023 //
GLOBENEWSWIRE
European Commission approves haematology biosimilar
30 May 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
1-Year Outcomes of PIII Study for SB15, Proposed biosimilar to Eylea, Presented
24 Apr 2023 //
GLOBENEWSWIRE
Samsung Bioepis to Present New Data for SB15, biosimilar to Eylea (aflibercept)
20 Apr 2023 //
GLOBENEWSWIRE
Samsung Bioepis Releases its First US Biosimilar Market Report
17 Apr 2023 //
GLOBENEWSWIRE
Samsung Bioepis Receives Positive CHMP Opinion for Eculizumab Biosimilar
31 Mar 2023 //
GLOBENEWSWIRE
Samsung Bioepis Presents Phase 1 Study Results of SB17 (Ustekinumab)
17 Mar 2023 //
GLOBENEWSWIRE
Samsung Announces Health Canada Approval of Citrate-Free High-Concn. of HUMIRA
03 Jan 2023 //
GLOBENEWSWIRE
Samsung Bioepis speeding up US launch of Humira biosimilar
01 Jan 2023 //
KOREAHERALD
